AstraZeneca's Imfinzi Approved In EU For Muscle-Invasive Bladder Cancer

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that Imfinzi (durvalumab) has been approved in the European Union for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin https://www.nasdaq.com/articles/astrazenecas-imfinzi-approved-eu-muscle-invasive-bladder-cancer